| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3347305 | Diagnostic Microbiology and Infectious Disease | 2011 | 4 Pages |
Abstract
Oritavancin exhibited lower MIC50 values (0.03 and 0.5 mg/L) than comparators against methicillin-resistant Staphylococcus aureus (MRSA, n = 50) and vancomycin-intermediate SA strains (n = 60). At subtherapeutic concentrations, oritavancin demonstrated rapid (within 9 h) and concentration-dependent bactericidal activity against daptomycin nonsusceptible (DNS) MRSA. Further investigations are warranted to determine the therapeutic potential of oritavancin against DNS MRSA.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Céline Vidaillac, Jorge Parra-Ruiz, Michael Joseph Rybak,